{"id":"W2017709949","doi":"10.1160/th12-03-0209","title":"Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor","year":2012,"lang":"en","type":"review","venue":"Thrombosis and Haemostasis","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University","funders":"Allergan; Bayer HealthCare; Pfizer","keywords":"Rivaroxaban; Apixaban; Medicine; Dabigatran; Clinical trial; Discovery and development of direct thrombin inhibitors; Direct thrombin inhibitor; Intensive care medicine; Atrial fibrillation; Deep vein; Stroke (engine); Thrombosis; Venous thrombosis; Warfarin; Surgery; Internal medicine; Thrombin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005834443,0.001505731,0.002684202,0.007073244,0.000753963,0.001800917,0.004299656,0.004963642,0.01017467],"category_scores_gemma":[0.008392211,0.000751058,0.002737159,0.006820324,0.001032937,0.002612751,0.001862865,0.00339449,0.006740988],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002892978,"about_ca_system_score_gemma":0.01116737,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005699853,"about_ca_topic_score_gemma":0.006539188,"domain_scores_codex":[0.9946226,0.001272871,0.001965872,0.0004097213,0.001557309,0.0001716751],"domain_scores_gemma":[0.994435,0.001308744,0.001154748,0.0001296424,0.002775453,0.0001965338],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007580682,0.000102862,0.0002916673,0.05139318,0.0001989319,0.000412768,0.0004174006,0.0003809638,0.0007677707,0.007570218,0.3463437,0.5920447],"study_design_scores_gemma":[0.000067074,0.0000409481,0.0008838356,0.05110203,0.0002547434,0.0009034971,0.0002200749,0.0001096883,0.0002216508,0.003929161,0.9422364,0.00003099476],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003625503,0.9389538,0.004457576,0.03373062,0.005015687,0.0007055731,0.00135796,0.0001392473,0.01527688],"genre_scores_gemma":[0.003057533,0.9372154,0.03004698,0.01673187,0.001082124,0.001058296,0.003164874,0.00004623505,0.007596637],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01017467,"threshold_uncertainty_score":0.03403765,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.348422928205051,"score_gpt":0.4101086491624937,"score_spread":0.06168572095744268,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}